Alexander J Stockdale1, Richard Odame Phillips2, Apostolos Beloukas1, Lambert Tetteh Appiah3, David Chadwick4, Sanjay Bhagani5, Laura Bonnett6, Fred Stephen Sarfo2, Geoffrey Dusheiko7, Anna Maria Geretti1. 1. Institute of Infection and Global Health, University of Liverpool, United Kingdom. 2. Department of Medicine, Kwame Nkrumah University of Science and Technology Komfo Anokye Teaching Hospital, Kumasi, Ghana. 3. Komfo Anokye Teaching Hospital, Kumasi, Ghana. 4. Centre for Clinical Infection, James Cook University Hospital, Middlesbrough. 5. Department of Infectious Diseases, Royal Free Hospital, London. 6. Institute of Infection and Global Health, University of Liverpool, United Kingdom Department of Biostatistics, University of Liverpool. 7. Division of Medicine, University College London, United Kingdom.
Abstract
BACKGROUND: Antiretroviral treatment (ART) programs in sub-Saharan Africa have for many years included lamivudine as the sole hepatitis B virus (HBV) inhibitor. Long-term outcomes and the effects of introducing tenofovir as part of ART in these populations have not been characterized. METHODS: The study comprised a cross-sectional analysis of 106 human immunodeficiency virus (HIV)/HBV-coinfected subjects maintained on lamivudine, as well as a prospective analysis of 76 lamivudine-experienced subjects who introduced tenofovir. Patients underwent assessment of liver fibrosis by transient elastography (TE) and testing to characterize HIV type 1 (HIV-1) and HBV replication. RESULTS: After a median of 45 months of lamivudine treatment, HIV-1 RNA and HBV DNA were detectable in 35 of 106 (33.0%) and 54 of 106 (50.9%) subjects, respectively, with corresponding drug resistance rates of 17 of 106 (16.0%) and 31 of 106 (29.2%), respectively. Median TE values were 5.7 kPa (interquartile range, 4.7-7.2 kPa) and independently associated with HBV DNA load, aspartate aminotransferase levels, and platelet counts; 13 of 106 (12.3%) subjects had TE measurements >9.4 kPa. Twelve months after the first assessment, and a median of 7.8 months after introducing tenofovir, HBV DNA levels declined by a mean of 1.5 log10 IU/mL (P < .001). TE values changed by a mean of -0.2 kPa (P = .097), and declined significantly in subjects who had pretenofovir HBV DNA levels >2000 IU/mL (mean, -0.8 kPa; P = .048) or TE values >7.6 kPa (mean, -1.2 kPa; P = .021). HIV-1 RNA detection rates remained unchanged. CONCLUSIONS: A proportion of HIV/HBV-coinfected patients on long-term lamivudine-containing ART had poor HIV and HBV suppression, drug resistance, and TE values indicative of advanced liver fibrosis. Tenofovir improved HBV control and reduced liver stiffness in subjects with high HBV DNA load and TE values.
BACKGROUND: Antiretroviral treatment (ART) programs in sub-Saharan Africa have for many years included lamivudine as the sole hepatitis B virus (HBV) inhibitor. Long-term outcomes and the effects of introducing tenofovir as part of ART in these populations have not been characterized. METHODS: The study comprised a cross-sectional analysis of 106 human immunodeficiency virus (HIV)/HBV-coinfected subjects maintained on lamivudine, as well as a prospective analysis of 76 lamivudine-experienced subjects who introduced tenofovir. Patients underwent assessment of liver fibrosis by transient elastography (TE) and testing to characterize HIV type 1 (HIV-1) and HBV replication. RESULTS: After a median of 45 months of lamivudine treatment, HIV-1 RNA and HBV DNA were detectable in 35 of 106 (33.0%) and 54 of 106 (50.9%) subjects, respectively, with corresponding drug resistance rates of 17 of 106 (16.0%) and 31 of 106 (29.2%), respectively. Median TE values were 5.7 kPa (interquartile range, 4.7-7.2 kPa) and independently associated with HBV DNA load, aspartate aminotransferase levels, and platelet counts; 13 of 106 (12.3%) subjects had TE measurements >9.4 kPa. Twelve months after the first assessment, and a median of 7.8 months after introducing tenofovir, HBV DNA levels declined by a mean of 1.5 log10 IU/mL (P < .001). TE values changed by a mean of -0.2 kPa (P = .097), and declined significantly in subjects who had pretenofovir HBV DNA levels >2000 IU/mL (mean, -0.8 kPa; P = .048) or TE values >7.6 kPa (mean, -1.2 kPa; P = .021). HIV-1 RNA detection rates remained unchanged. CONCLUSIONS: A proportion of HIV/HBV-coinfected patients on long-term lamivudine-containing ART had poor HIV and HBV suppression, drug resistance, and TE values indicative of advanced liver fibrosis. Tenofovir improved HBV control and reduced liver stiffness in subjects with high HBV DNA load and TE values.
Authors: Richard K Sterling; Wendy C King; Abdus S Wahed; David E Kleiner; Mandana Khalili; Mark Sulkowski; Raymond T Chung; Mamta K Jain; Mauricio Lisker-Melman; David K Wong; Marc G Ghany Journal: Hepatology Date: 2019-08-19 Impact factor: 17.425
Authors: Robert C Bollinger; Chloe L Thio; Mark S Sulkowski; Jane McKenzie-White; David L Thomas; Charles Flexner Journal: Lancet HIV Date: 2019-12-20 Impact factor: 12.767
Authors: Timothy Na Archampong; Ceejay L Boyce; Margaret Lartey; Kwamena W Sagoe; Adjoa Obo-Akwa; Ernest Kenu; Jason T Blackard; Awewura Kwara Journal: Antivir Ther Date: 2016-05-11
Authors: Michael J Vinikoor; Lloyd Mulenga; Alice Siyunda; Kalo Musukuma; Roma Chilengi; Carolyn Bolton Moore; Benjamin H Chi; Mary-Ann Davies; Matthias Egger; Gilles Wandeler Journal: Trop Med Int Health Date: 2016-08-30 Impact factor: 2.622
Authors: Kasha P Singh; Megan Crane; Jennifer Audsley; Anchalee Avihingsanon; Joe Sasadeusz; Sharon R Lewin Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Martin Tibuakuu; Caroline Jjingo; Gregory Dale Kirk; David Lee Thomas; Ronald Gray; Victor Ssempijja; Fred Nalugoda; David Serwadda; Ponsiano Ocama; Christopher Kenneth Opio; David Erwin Kleiner; Thomas Charles Quinn; Steven James Reynolds Journal: J Viral Hepat Date: 2020-06-09 Impact factor: 3.517
Authors: Michael J Vinikoor; Edford Sinkala; Roma Chilengi; Lloyd B Mulenga; Benjamin H Chi; Zude Zyambo; Christopher J Hoffmann; Michael S Saag; Mary-Ann Davies; Matthias Egger; Gilles Wandeler Journal: Clin Infect Dis Date: 2017-05-15 Impact factor: 9.079
Authors: Philippa C Matthews; Apostolos Beloukas; Amna Malik; Jonathan M Carlson; Pieter Jooste; Anthony Ogwu; Roger Shapiro; Lynn Riddell; Fabian Chen; Graz Luzzi; Manjeetha Jaggernath; Gerald Jesuthasan; Katie Jeffery; Thumbi Ndung'u; Philip J R Goulder; Anna Maria Geretti; Paul Klenerman Journal: PLoS One Date: 2015-07-28 Impact factor: 3.240